Progression of liver fibrosis in post-transplant hepatitis C: Mechanisms, assessment and treatment

被引:108
作者
Berenguer, Marina [1 ,2 ]
Schuppan, Detlef [3 ,4 ]
机构
[1] Univ Valencia, Dept Med, Hepatol & Liver Transplantat Unit, La Fe Hosp, E-46003 Valencia, Spain
[2] Inst Salud Carlos III, Natl Network Ctr Hepatol & Gastroenterol Res, CIBEREHD, Madrid, Spain
[3] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med 1, D-55116 Mainz, Germany
[4] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA
关键词
Antifibrotic; Biopsy; Cirrhosis; Collagen; Elastography; Fibrosis; HCV; Hepatic stellate cell; Interferon; Liver; Macrophage; NAFLD; Post-transplant; Progression; Second hit; T cell; TGFbeta; Serum marker; Transplantation; VENOUS-PRESSURE GRADIENT; VIRUS CORE PROTEIN; OPEN-LABEL SERIES; SUSTAINED VIROLOGICAL RESPONSE; TRANSPLANT RECIPIENTS; ANTIVIRAL THERAPY; PEGYLATED-INTERFERON; TRANSIENT ELASTOGRAPHY; STELLATE CELLS; CLINICAL-IMPLICATIONS;
D O I
10.1016/j.jhep.2012.12.014
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Liver fibrosis results from an excessive wound healing response in most chronic liver diseases, such as hepatitis C. Despite great advances in antiviral therapy in recent years, progressive liver fibrosis remains a major problem for patients with recurrent hepatitis C after liver transplantation. Liver biopsy remains a central tool in the management of HCV-positive liver transplant recipients, but reliable non-invasive methods for the assessment of liver fibrosis, such as ultrasound elastography, are increasingly being incorporated in the management of post-transplant patients, helping predict prognosis, guide treatment decisions, and stratify patients for emerging antifibrotic therapies. In this manuscript, we will review the natural history as well as tools to monitor fibrosis progression in the HCV-positive liver transplant recipient, the mechanisms underlying rapid fibrosis progression in up to 30% of these patients, the effect of antiviral therapies and highlight promising antifibrotic approaches. (c) 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1028 / 1041
页数:14
相关论文
共 160 条
  • [41] Donor and Recipient IL28B Polymorphisms in HCV-Infected Patients Undergoing Antiviral Therapy before and after Liver Transplantation
    Coto-Llerena, M.
    Perez-del-Pulgar, S.
    Crespo, G.
    Carrion, J. A.
    Martinez, S. M.
    Sanchez-Tapias, J. M.
    Martorell, J.
    Navasa, M.
    Forns, X.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 (05) : 1051 - 1057
  • [42] Non-invasive assessment of fibrosis in liver grafts due to hepatitis C virus recurrence
    Cross, Timothy J. S.
    Jothimani, Dinesh
    Heneghan, Michael A.
    Harrison, Phillip M.
    [J]. CLINICAL TRANSPLANTATION, 2011, 25 (03) : 345 - 351
  • [43] Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
    Cusi, Kenneth
    [J]. GASTROENTEROLOGY, 2012, 142 (04) : 711 - U109
  • [44] HEPATIC HISTOLOGICAL-FINDINGS AFTER TRANSPLANTATION FOR CHRONIC HEPATITIS-B VIRUS-INFECTION, INCLUDING A UNIQUE PATTERN OF FIBROSING CHOLESTATIC HEPATITIS
    DAVIES, SE
    PORTMANN, BC
    OGRADY, JG
    ALDIS, PM
    CHAGGAR, K
    ALEXANDER, GJM
    WILLIAMS, R
    [J]. HEPATOLOGY, 1991, 13 (01) : 150 - 157
  • [45] Evolution of Hepatitis C Virus in Liver Allografts
    Demetris, Anthony J.
    [J]. LIVER TRANSPLANTATION, 2009, 15 (11) : S35 - S41
  • [46] Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon
    Di Bisceglie, Adrian M.
    Shiffman, Mitchell L.
    Everson, Gregory T.
    Lindsay, Karen L.
    Everhart, James E.
    Wright, Elizabeth C.
    Lee, William M.
    Lok, Anna S.
    Bonkovsky, Herbert L.
    Morgan, Timothy R.
    Ghany, Marc G.
    Morishima, Chihiro
    Snow, Kristin K.
    Dienstag, Jules L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (23) : 2429 - 2441
  • [47] A 7-gene signature of the recipient predicts the progression of fibrosis after liver transplantation for hepatitis C virus infection
    do O, Nicole T.
    Eurich, Dennis
    Schmitz, Petra
    Schmeding, Maximilian
    Heidenhain, Christoph
    Bahra, Marcus
    Trautwein, Christian
    Neuhaus, Peter
    Neumann, Ulf P.
    Wasmuth, Hermann E.
    [J]. LIVER TRANSPLANTATION, 2012, 18 (03) : 298 - 304
  • [48] Portal Fibroblasts: Underappreciated Mediators of Biliary Fibrosis
    Dranoff, Jonathan A.
    Wells, Rebecca G.
    [J]. HEPATOLOGY, 2010, 51 (04) : 1438 - 1444
  • [49] Interleukin-28B polymorphism in hepatitis C and liver transplantation
    Duarte-Rojo, Andres
    Deneke, Matthew G.
    Charlton, Michael R.
    [J]. LIVER TRANSPLANTATION, 2013, 19 (01) : 49 - 58
  • [50] Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination
    Dumoriter, J
    Scoazec, JY
    Chevallier, P
    Boillot, O
    [J]. JOURNAL OF HEPATOLOGY, 2004, 40 (04) : 669 - 674